Saturday, May 21, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

A critical subset of supporting cells may lie at the origins of rare autoimmune disease

by Medical Finance
in News
A critical subset of supporting cells may lie at the origins of rare autoimmune disease
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Supporting actors sometimes steal the show. In a new study published today in Cell, researchers headed by Prof. Ido Amit at the Weizmann Institute of Science have shown that supporting cells called fibroblasts, long viewed as uniform background players, are in fact extremely varied and vital. A subset of these cells, according to the study, may lie at the origins of scleroderma – a rare autoimmune disease. The findings open a new direction for developing a future therapy against this devastating, incurable disorder.

Scleroderma (from the Greek skleros, meaning “hard,” and derma, meaning “skin”) is characterized by the formation of an abnormally hard, inflexible layer of skin on the arms, legs and face. Its manifestations vary greatly among patients. In about a third of the cases, the disease, which mainly strikes women aged 30 to 50, advances rapidly and spreads beyond the extremities, causing life-threatening damage to internal organs. Immune-regulating drugs that normally bring relief to people with autoimmune diseases are less effective in scleroderma, which has a higher mortality rate than other rheumatic disorders.

“Scleroderma is one of the most frustrating disorders to treat – we can alleviate some of the patient’s symptoms, but usually we cannot significantly affect the cause of the disease, block its progression or reverse its course,” says Prof. Chamutal Gur, a senior physician in the Rheumatology Department at Hadassah University Medical Center, who led the new study in Amit’s lab in Weizmann’s Immunology Department. Her interest in this disease is not only professional: Two of her cousins have been diagnosed with scleroderma. When she joined Amit’s lab as a postdoctoral fellow some three years ago, her goal was to get to the root of this puzzling disease.

Gur and colleagues launched a study of scleroderma using technologies developed in Amit’s lab for simultaneously exploring the genetic material of thousands of individual cells. These technologies, known as single-cell RNA sequencing, reveal each cell’s unique identity. The study was conducted in collaboration with Dr. Hagit Peleg, Dr. Suhail Aamar, Dr. Fadi Kharouf, Dr. Anat Elazary and other rheumatologists at Hadassah University Medical Center, and with Prof. Alexandra Balbir-Gurman, who supervised the clinical aspect of the study, and Dr. Yolanda Braun-Moscovici, both of the Rambam Health Care Campus.

The researchers collected skin samples from nearly 100 scleroderma patients and from more than 50 healthy volunteers who served as a control group, in the largest-ever study of this kind to explore the disease. While perfecting the sample collection technique, Gur performed nearly 20 skin biopsies on herself.

As scleroderma is considered an autoimmune disorder – that is, one in which the immune system attacks the person’s own body – the researchers looked for immune cell differences between the control and patient groups. But contrary to what would be expected of an autoimmune disease, the analysis failed to reveal a characteristic, global pattern of immune abnormalities in most of the patients. Instead, to their surprise, the researchers found it were the patients’ fibroblasts that differed significantly from those of the controls.

Aside from roles in growth and wound healing, fibroblasts were thought to be mere “scaffolding” holding cells in place. The new study challenges this humdrum picture: The researchers found that fibroblasts can be divided into about ten major groups, each performing different and often vital functions, from conveying immune system signals to affecting metabolism, blood clotting and blood vessel formation. These groups can be further broken into some 200 subtypes.

Most importantly, the researchers managed to identify a subset of fibroblast whose concentration drops sharply in the early stages of scleroderma. They named these cells Scleroderma-Associated Fibroblasts, abbreviated as ScAFs (which is also short for “scaffold”). Whereas in healthy controls ScAFs accounted for nearly 30 percent of all fibroblasts, this percentage decreased dramatically in scleroderma patients and continued to plummet as the disease progressed.

The researchers mapped out the locations of ScAFs deep within skin tissue, and they tapped these cells’ RNA to determine what changes a functional ScAF into a malfunctioning cell common in scleroderma patients. They also identified biological markers correlated with specific kinds of organ damage; these markers can help physicians administer a personalized treatment, in order to prevent life-threatening complications. The research also revealed ScAF-related signaling pathways that can be targeted in future scleroderma therapies.

The reduction in the size of a critical subset of fibroblasts appears to be an early event in the course of scleroderma. It might be possible to design a therapy that will make up for this loss, slowing the progression of the disease.”


Prof. Ido Amit, Weizmann Institute of Science

“Our approach is relevant to other diseases,” adds Dr. Shuang-Yin Wang of Amit’s lab, who led the study’s data analysis using artificial intelligence tools. “It reveals the enormous potential of meticulous tissue analysis involving advanced single-cell technologies for uncovering disease dynamics.”

“Integrating the latest single-cell genomic research techniques with clinical data can shed new light on diseases whose origins are currently obscure,” Amit concludes.

Source:

Weizmann Institute of Science

Journal reference:

Gur, C., et al. (2022) LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma. Cell. doi.org/10.1016/j.cell.2022.03.011.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Scientists discover a division of labor between genetic switches

Study helps understand actionable genetic variation affecting drugs in the Middle East population

by Medical Finance
May 21, 2022
0

A group of researchers at Qatar Foundation have reported the first comprehensive study of the distribution of actionable genetic variation...

Ultra-rapid genome sequencing technology can detect rare genetic diseases in eight hours

Global human microbiome research dominated by highly developed countries

by Medical Finance
May 21, 2022
0

New studies emerge daily on the effect of the human microbiome on human health: colon cancer, ulcers, and cognitive conditions...

Scrapping many Covid testing measures is a grave mistake, says London Medical Laboratory

Study shows how some cancer cells immobilize T cells

by Medical Finance
May 21, 2022
0

Our immune systems have the potential to find and destroy cancer cells. But cancer cells can be clever and develop...

Peptide-enhanced antibody therapy may help treat breast cancer metastasis to bone

Regulatory sequences in the genomes of mammals help explain how cancer invades normal tissues

by Medical Finance
May 21, 2022
0

Researchers from UConn Heath and Yale University have made new advances connecting the evolution of pregnancy and cancer metastasis. Publishing...

Study identifies a new potential pathway for developing therapeutics against Epstein-Barr virus

New method decodes the role of DDX41 protein in preventing double-strand breaks in DNA

by Medical Finance
May 21, 2022
0

There are many different ways in which the genetic material DNA can be damaged, resulting in the development of diseases...

ANU researchers identify why Th17 cells go rogue and promote the onset of multiple sclerosis

Twin study identifies the influence of environment and genetics in multiple sclerosis

by Medical Finance
May 21, 2022
0

Researchers at the University of Zurich and Munich's LMU Klinikum hospital have studied the immune system of pairs of monozygotic...

Next Post
Study: Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. Image Credit: NIAID

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Synthetic Virions Reveal Fatty Acid-Coupled Adaptive Immunogenicity Of SARS-Cov-2 Spike Glycoprotein. Image Credit: Design_Cells / Shutterstock.com
    Mechanism of fatty-acid coupled adaptive immunity in SARS-CoV-2 revealed
  • Study: Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron Variant, Spain. Image Credit: Artindo/Shutterstock
    Epidemiologic characteristics of SARS-CoV-2 Omicron and Delta variant infection cases in Cantabria, Spain
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply